retatrutide phase 2 trial type 2 diabetes results 2024 produces up to 30.3% weight loss in 3 retatrutide phase 2 trial type

An observational study published in 2023 in Diabetes Care that looked to determine whether the use of GLP-1 medications was associated with an increased risk of thyroid cancer found that in 1-3 years of treatment, the risk for thyroid cancer was increased for those taking GLP-1 medications (2)

So while the raw numbers show headaches in trial participants, the signal was not strong enough relative to placebo to warrant special labeling

For clarity, only the losses obtained for the highest dose of tirzepatide (15 mg) are shown in the figure

Compared to other drugs within the same class, Exenatide lags behind in terms of documented cardiovascular advantages

[15] Even more impressive

While GLP-1 medications provide powerful support for weight management, the degree of weight loss depends heavily on adherence to a modest caloric deficit below total daily energy expenditure and on engaging in regular physical activity to increase caloric utilization, he explains